Knowledge and perspectives towards the use of histology in inflammatory bowel disease by gastroenterologists across the Asia-Pacific region

Thanaboon Chaemsupaphan; Aviv Pudipeddi; Huiyu Lin; Hsin-Yun Wu; Julajak Limsrivilai; Wee Chian Lim; Shu-Chen Wei; Rupert W. Leong

doi:10.5217/ir.2024.00086

Articles

Page Path: HOME > Intest Res > Volume 23(3); 2025 > Article

Original Article IBD Knowledge and perspectives towards the use of histology in inflammatory bowel disease by gastroenterologists across the Asia-Pacific region: Thanaboon Chaemsupaphan^1,2,*, Aviv Pudipeddi^1,3,*, Huiyu Lin^1,4, Hsin-Yun Wu⁵, Julajak Limsrivilai², Wee Chian Lim⁴, Shu-Chen Wei⁶, Rupert W. Leong^1,3,7; Intestinal Research 2025;23(3):338-346.
DOI: https://doi.org/10.5217/ir.2024.00086
Published online: December 2, 2024

¹Department of Gastroenterology and Liver Services, Concord Repatriation General Hospital, Sydney, Australia

²Division of Gastroenterology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

³Faculty of Medicine and Health, University of Sydney, Sydney, Australia

⁴Department of Gastroenterology, Tan Tock Seng Hospital, Singapore

⁵Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital Jinshan branch, New Taipei City, Taiwan

⁶Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

⁷Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia

Correspondence to Rupert W. Leong, Department of Gastroenterology and Liver Services, Concord Hospital Level 1 West, Hospital Rd, Concord, New South Wales 2137, Australia. E-mail: ruperleong@outlook.com

The first two authors contributed equally to this study.

• Received: June 16, 2024 • Revised: September 20, 2024 • Accepted: September 21, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

4,522 Views
191 Download
2 Web of Science
2 Crossref
2 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
Supplementary Material
REFERENCES

Abstract

Background/Aims
Recently, histological mucosal assessment has gained momentum as a potential new treatment target for patients with inflammatory bowel disease (IBD) in the Asia-Pacific region. This study aimed to evaluate and compare the knowledge and acceptability of histological assessment among gastroenterologists across the region.
Methods
A cross-sectional survey among gastroenterologists in the Asia-Pacific region was conducted and compared against a previous Australian survey. The questionnaire assessed knowledge and attitude towards the role and application of histology in IBD practice. Statistical analyses were employed to compare scores and identify predictors.
Results
A total of 221 gastroenterologists from 12 countries, including 77 (34.8%) from Australia, responded to questionnaire, with 185 (83.7%) completing the survey. The mean knowledge score was 9.8 ± 3.3 (51.6%). There was no significant difference in the average score among countries (P= 0.53). IBD specialist (P< 0.01), doctoral degree (P= 0.02), and regular participation in IBD multidisciplinary meetings (P= 0.01) were associated with higher scores. Most respondents (90.7%) agreed on the importance of histology in IBD. While 54.6% of Australians perceived the role of histology as established, only 37.0% of Asians respondents considered this similarly (P= 0.02). Histological activity alone minimally influences treatment escalation in patients with endoscopic remission, but achieving combined histo-endoscopic remission often leads to therapy de-escalation.
Conclusions
Although gastroenterologists in the Asia-Pacific region are aware of the role of histology in IBD, their knowledge remains limited, and its clinical utility is not widely adopted. There is a need to promote the routine use of standardized histological assessment in IBD practice.
Keywords: Histological assessment; Inflammatory bowel diseases; Histology; Survey; Asia-Pacific

INTRODUCTION

Inflammatory bowel disease (IBD), comprising ulcerative colitis (UC) and Crohn’s disease, presents a significant healthcare challenge globally, with its prevalence steadily rising, particularly in the Asia-Pacific region [1-3]. This chronic inflammatory condition manifests with relapsing episodes, often leading to debilitating outcomes such as hospitalization, surgical interventions, and diminished quality of life [4]. The conventional approach to managing IBD has focused on achieving clinical and endoscopic remission, as advocated by the Selecting Therapeutic Targets in Inflammatory Bowel Disease-II consensus [5]. However, emerging evidence suggests that histological assessment and outcome may also play a pivotal role in understanding disease activity and predicting long-term outcomes of IBD patients [6-8].

While histological remission has been recognized in most contemporary clinical drug trials, its formal integration as a treatment target in routine practice remains unexplored. Despite recent surveys indicating a high level of awareness regarding the significant role of histology in IBD [9], there remains a substantial gap in both knowledge and utilization of histopathology among gastroenterologists and pathologists. This underscores the critical need to enhance education among clinicians, which may help on conducting further research in this topic and ensuring greater familiarity in clinical practice.

Given lower IBD prevalence, it is not known whether gastroenterologists in Asia-Pacific region are aware of or utilize histopathological assessment. Variability in practice standards among Asian countries might also include the availability of gastroenterologists to interpret biopsy results. In this context, we expanded our survey to evaluate the knowledge of histological assessment in IBD among healthcare professionals in the Asia-Pacific region. Additionally, we sought to assess their attitudes towards the role of histology in IBD assessment and management, with a particular focus on comparing Australian and Asian practices. We hypothesized that Australian healthcare professionals may have more extensive knowledge and experience with histological assessment in IBD compared to Asian gastroenterologists due to a greater volume of IBD-focused work. While knowledge about histological assessment in IBD may be increasing in Asian countries, its integration into routine clinical practice may still be limited due to resource limitations. Comparing attitudes and practices among these countries will help identify disparities and promote the harmonization of histological approach to enhance patient care standards across the Asia-Pacific region.

METHODS

We conducted a prospective, cross-sectional survey of gastroenterologists in the Asia-Pacific region from May to September 2023. This survey was administered online, disseminated through members of the Asian Pacific Association of Gastroenterology and their affiliated local societies. The data obtained from this survey were amalgamated with that from a prospective, cross-sectional survey of Australian gastroenterologists conducted earlier in 2022 [9]. In the Australian survey, healthcare professionals were contacted by proxy through the Gastroenterological Society of Australia to participate. The questionnaire used in both surveys contained identical questions. Participation in the survey was voluntary, and consent was implied by the completion of the survey. No personally identifiable data were collected from the participants, and there were no questions linking patients. The study was approved by the Sydney Local Health District Human Research Ethics Committee (HREC 2021/PID00882).

1. Survey on Attitudes and Knowledge towards Histology in IBD

The structured survey was developed by a team of gastroenterologists, drawing from the European Crohn’s and Colitis Organisation (ECCO) position paper on histopathology [10,11], and biopsy reporting guidelines of the British Society of Gastroenterology [12]. The survey encompassed demographic details and practice locations of respondents. Attitudes towards the histology and its application in clinical practice were asked through 8 questions (Supplementary Material). Additionally, the survey comprised 18 questions assessing histological knowledge, covering important topics such as commonly used histological scoring systems, including Truelove and Richards Index [13], Modified Riley score [14], Geboes score [15], Nancy histological index (NHI) [16], Robarts histopathology index (RHI) [17], and the potential role of histological assessment in managing IBD. This questionnaire was discriminately validated by comparing responses from senior and junior gastroenterologists practicing in Australia who were not involved with the questionnaire development. A knowledge score was derived by summing correct responses, with a maximum possible score of 19.

2. Statistical Analysis

Continuous variables were depicted as mean ± standard deviation, while categorical variables were represented by the number of subjects and corresponding percentages. To compare the knowledge of IBD histology across different factors, a standard independent t-test and chi-square test were employed. One-way analysis of variance was used to compare the means of more than 2 continuous variables. Predictors of IBD histology knowledge scores were determined through linear regression analysis. A significance level of < 0.05, two-tailed, was deemed statistically significant. All statistical analyses were conducted using STATA 17.0 (Stata Corporation, College Station, TX, USA).

RESULTS

The study involved a total of 221 gastroenterologists from 12 countries across the Asia-Pacific region. The 3 countries with the highest number of respondents were Australia (n = 77, 34.8%), Taiwan (n = 41, 18.6%), and Singapore (n = 32, 14.5%). Detailed demographic information is shown in Table 1. Out of the total, 185 respondents (83.7%) completed the survey, with a mean completion time of 9.39 minutes. The majority of respondents fell within the 31 to 40 years age group and held either Doctor of Medicine (MD), Bachelor of Medicine, Bachelor of Surgery (MBBS), or a gastroenterologist fellowship degree. Approximately one-third were general gastroenterologists, another one-third specialized in IBD, and 15.8% were in training. Most of the respondents worked in public hospitals and reported seeing at least 5 IBD patients each week in their respective hospitals. Nearly half (48%) reported regular participation in IBD multidisciplinary team (MDT) meetings, occurring at least once a month in their IBD unit. Besides the respondents, surgeons were the most frequent participants in the MDT meetings, followed by radiologists and pathologists, respectively. No differences were observed in demographic data between Australian and non-Australian respondents.

1. Knowledge of Histology in IBD across the Asia-Pacific Region

The mean IBD histological knowledge score among 185 respondents was 9.8 ± 3.3 out of 19 (51.6%). The mean scores of the majority of respondents, including those from Australia, Singapore, Taiwan, and Thailand, were 9.2 ± 3.2, 10.8 ± 3.6, 10.5 ± 4.0, and 9.6 ± 1.8, respectively (Fig. 1). While the difference in mean scores among each country was not statistically significant (P= 0.53), there was a trend toward higher knowledge scores in Asian countries compared to Australia (P= 0.06). Gastroenterologists specialized in IBD had significantly higher knowledge scores compared to non-IBD gastroenterologists (P< 0.01; mean difference, –2.26; 95% confidence interval [CI], –3.25 to –1.27) (Fig. 2). Gastroenterologists holding a Doctor of Philosophy (PhD) degree exhibited higher knowledge scores relative to those with lower degrees (P= 0.02; mean difference, –1.34; 95% CI, –2.47 to –1.99). Gastroenterologists who regularly participated in IBD-focused MDT meetings had higher knowledge scores compared to those who did not have meetings in their hospitals (P= 0.01; mean difference, –1.27; 95% CI, –2.22 to –0.32). There were no significant differences in knowledge scores between gastroenterologists working in public or university hospitals compared to those in private hospitals (P= 0.16; mean difference, –0.99; 95% CI, –2.38 to 0.38). Similarly, no significant differences were observed between practicing gastroenterologists and those still in training (P= 0.28; mean difference, –0.70; 95% CI, –2.02 to 0.61). Data for Asian and Australian respondents are presented separately in Supplementary Fig. 1. Among the validated histological scoring systems, including the NHI and RHI scores, only 42 respondents (22.7%) were aware of the NHI remission cutoff of 0, and only 28 respondents (15.1%) were aware of the RHI cutoff level of ≤ 3 to identify histological remission. Fig. 3 shows the comparison of histological remission knowledge for each scoring system. IBD specialists are more aware of both remission endpoints than those who are not specialized in IBD (P< 0.01).

We identified several predictive factors associated with adequate histological knowledge, using a knowledge score of greater than 10 as the threshold. Among all respondents, being an IBD specialist was strongly associated with higher knowledge scores in both univariable (odds ratio [OR], 3.55; 95% CI, 1.86 to 6.75; P< 0.01) and multivariable analyses (OR, 2.66; 95% CI, 1.30 to 5.45; P= 0.01). Holding a PhD degree and regular MDT participation also showed significance in univariable analysis (OR, 2.81; 95% CI, 1.40 to 5.68; P< 0.01 and OR, 2.14; 95% CI, 1.18 to 3.89; P= 0.01, respectively) but not in multivariable analysis. The results of univariate and multivariate analyses for each subgroup are demonstrated in Table 2.

2. Attitudes towards Histology and Scoring Systems in IBD

Overall, respondents widely agreed on the significance of histology in IBD, with a majority describing this as “emerging” (47.3%) or “established” (43.4%). Notably, while 54.6% of Australian gastroenterologists perceived the role of histology as established, only 37.0% of respondents from Asia considered similarly (P= 0.02) (Fig. 4A). Similarly, Australian gastroenterologists supported the idea that achieving histological remission is more crucial than endoscopic remission, with 65.0% agreement, while only 18.5% of Asian respondents agreed on this statement. The respondents reported that 65.4% of the official IBD pathological reports do not incorporate histological scoring systems. Among the standard scores, the NHI was the most widely utilized (75.0%), followed by the Geboes score (10.9%). A significant proportion of Australian respondents (28.6% always and 29.9% sometimes) showed a preference for utilizing scoring systems. Conversely, Asian respondents have not yet preferred, with 33.3% indicating never and 27.8% rarely (Fig. 4B).

3. Impact of Histological Information on Clinical Practice

The extent of histological activity in influencing IBD management was explored (Supplementary Table 1). Most gastroenterologists indicated that histological activity would not prompt a change in treatment if patients were already in endoscopic remission. However, when combined with elevated fecal calprotectin, escalation of therapy was occasionally initiated. In cases where patients achieved combined histo-endoscopic remission during 2 consecutive colonoscopies, most gastroenterologists would consider treatment de-escalation (44.6% responded “often” and 12.7% reported “always”). Conversely, if a prior colonoscopy showed a Mayo endoscopic score (MES) of 1, fewer respondents would de-escalate treatment. An MES of 1 was insufficient for most gastroenterologists to de-escalate treatment. Given that histological activity might be linked to dysplasia, 67% of gastroenterologists would aim for histological remission in UC patients with additional risk factors for colorectal cancer.

DISCUSSION

Despite histological remission not yet being a formal treatment target in IBD, the concept of disease clearance has evolved to incorporate histological remission as an endpoint due to its association with a lower risk of hospitalization and disease relapse [18]. With this emerging knowledge, our team conducted a survey on gastroenterologists across the Asia-Pacific region to assess knowledge and attitudes towards the role of histology in IBD, aiming to understand the level of knowledge and their perspectives on histological assessment as a potential new treatment target. The survey found that the majority of gastroenterologists exhibited limited histological knowledge, scoring a mean of only 51.6%, with slightly higher scores in Asian respondents. Australian gastroenterologists demonstrated more supportive stance towards the role of histology in IBD practice, with substantial acceptance of histological remission as an ultimate goal of IBD treatment. Conversely, in Asia, while there was acknowledgment of this importance, the integration into clinical practice remained in the nascent stage.

A knowledge questionnaire based on the ECCO histopathology statement highlighted common IBD histological findings and treatment targets, including neutrophilic inflammation for defining histological activity, and absence of neutrophils, erosion, or ulceration for histological remission. Histological non-remission may predict complications and increase the risk of colonic neoplasia [19,20]. The NHI cutoff level of 0 and RHI of ≤ 3, which signify either the absence or mild increase of chronic inflammatory infiltrates, are recognized to determine histological remission [10,21]. Interestingly, respondents demonstrated insufficient knowledge of histological findings, as well as unawareness of cutoff levels for histological remission. Self-reporting as an IBD specialist is the predictive factor for better knowledge, implying that knowledge of this area is confined to a specific subgroup of gastroenterologists. While evidence supporting the benefits of histological remission is increasing, our survey found limited utilization of histology among respondents, who continue to prioritize biochemical and endoscopic outcomes. This highlights the urgent need to improve the histological knowledge in the Asia-Pacific region, especially among general gastroenterologists, to ensure standardized management and improved patient care.

Danese and his colleagues recently conducted a global survey on 359 participants from 60 countries on the real-world use of histological indices in UC [22]. Nearly all respondents (90.5%) use UC histology primarily for initial diagnosis whereas a smaller percentage use it to monitor or confirm disease remission. Our study, where all responses were from the AsiaPacific region, aligns with the global survey, indicating that up to 90% of respondents recognized the importance of the histological role in IBD. The disparities in IBD practice between Asia and Australia potentially led to differing attitudes in their histological applications. In Australia, where IBD has been acknowledged and extensively studied, along with abundant access to resources, including various non-gastroenterologist involvement in the unit, foster higher acceptance of histological assessments. Conversely, IBD practice in Asia has only gained prominence over the past decade [2,23]. Additionally, the historical emphasis on endoscopic technology in this region may limit the use of histology at present. The complexity of scoring systems and the absence of large prospective studies confirming the impact of histological activity on clinical outcomes of IBD patients are also significant factors contributing to the limited use of histological indices. It is important to note that although histology has become increasingly important, uncertainty remains regarding the optimal number and site of biopsies, as well as the ideal timing for assessment. The heterogeneity in practice across different countries also affect the interpretation of histological findings. Additionally, histological assessment in Crohn’s disease can be challenging due to the limited use of the histological index and the difficulty in accessing affected segments. Due to the current lack of robust data, histological endpoint cannot yet be considered a standard treatment outcome.

Our study is the first survey conducted on this topic in the Asia-Pacific region, carried out on behalf of large international gastroenterological organizations. It provides comprehensive data and comparative analysis of both Asian and Australian gastroenterologists, where the prevalence of IBD and establishment of practice differ significantly. This survey also covered multiple aspects, including the assessment of histological knowledge and the attitudes towards using histology in routine practice. However, there are some limitations. Firstly, the coverage of our survey was incomplete, as we did not receive responses from every country in the region, and the proportion of respondents from each country was disproportionate. Secondly, as an online survey, not all participants answered every question, which possibly due to the length of survey and language barriers. Nonetheless, the robust findings were supported by a substantial number of participants and consistent trends. Lastly, there was a temporal discrepancy between the Australian and Asian surveys which may have introduced nuances in histological knowledge.

In conclusion, while most gastroenterologists in the Asia-Pacific region are aware of the role of histology in IBD, they possess limited knowledge and do not routinely apply it in clinical practice. Enhancing histological knowledge and promoting the use of histological evaluations, possibly through implementing standardized reporting and artificial intelligence, conducting more histological studies, and building a consensus agreement in the region, will help gastroenterologists gain better comprehension and become more familiar with using standardized histological assessments.

NOTES

Funding Source

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of Interest

Leong RW is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Data Availability Statement

Data, analytic methods, and study materials are available to other researchers upon request.

Author Contributions

Conceptualization: Leong RW. Formal analysis: Chaemsupaphan T, Lin H. Investigation: Chaemsupaphan T, Pudipeddi A, Lin H, Wu HY, Limsrivilai J, Lim WC, Wei SC. Methodology: Chaemsupaphan T, Pudipeddi A, Lin H, Leong RW. Supervision: Leong RW. Writing - original draft: Chaemsupaphan T, Leong RW. Writing - review & editing: Pudipeddi A, Leong RW. Approval of final manuscript: all authors.

Additional Contributions

We would like to extend our gratitude to the Asian Pacific Association of Gastroenterology (APAGE) Steering Committee for Histology in Inflammatory Bowel Disease for their invaluable assistance in disseminating our survey.

Supplementary Material

Supplementary materials are available at the Intestinal Research website (https://www.irjournal.org).

Supplementary Material.

Inflammatory bowel disease histology survey questions

ir-2024-00086-Supplementary-Material.pdf

Supplementary Table 1.

Impact of Histological Information towards Clinical Practice

ir-2024-00086-Supplementary-Table-1.pdf

Supplementary Fig. 1.

Comparison of inflammatory bowel disease (IBD) histological knowledge among Asian (A) and Australian (B) respondents according to IBD subspecialty, educational degree, primary workplace, level of training, and participation in multidisciplinary team meeting. PhD, Doctor of Philosophy; MDT, multidisciplinary team.

ir-2024-00086-Supplementary-Fig-1.pdf

Fig. 1.

Mean inflammatory bowel disease (IBD) histological knowledge scores of overall respondents and the 4 most responsive countries. Values are shown in mean±standard deviation.

Fig. 2.

Forest plot comparing inflammatory bowel disease (IBD) histological knowledge of all respondents according to IBD subspecialty, educational degree, primary workplace, level of training, and participation in multidisciplinary team meeting. Values are shown in mean±standard deviation and mean difference with 95% confidence interval. PhD, Doctor of Philosophy; MDT, multidisciplinary team.

Fig. 3.

Comparison of knowledge of histological remission endpoint for each scoring system. (A-C) The remission endpoints of Geboes score, Nancy histological index, and Robart’s histological index are ≤2, 0, and ≤3, respectively.

Fig. 4.

Attitudes of gastroenterologists in the Asia-Pacific region towards the role of histology in clinical practice (A) and the current preference of using histological index in routine practice (B).

Table 1.

Demographic Data

Variable	Asian (n = 144)	Australian (n = 77)
Age group
21–30 yr	3 (2.1)	4 (5.2)
31–40 yr	75 (52.1)	30 (39.0)
41–50 yr	37 (25.7)	15 (19.5)
51–60 yr	21 (14.6)	19 (24.7)
> 60 yr	8 (5.6)	9 (11.7)
Countries of participants
Australia		77 (34.8)
Brunei	4 (1.8)
China	2 (0.9)
Hong Kong	9 (4.1)
India	1 (0.5)
Japan	5 (2.3)
Malaysia	6 (2.7)
Mongolia	1 (0.5)
Singapore	32 (14.5)
Taiwan	41 (18.6)
Thailand	21 (9.5)
South Korea	22 (10.0)
Predominant subspecialty (self-reported)
General gastroenterologist	44 (30.6)	32 (41.6)
Intervention endoscopist	18 (12.5)	4 (5.2)
Hepatologist	9 (6.3)	4 (5.2)
IBD	54 (37.5)	21 (27.3)
Gastroenterology trainee/fellow	19 (13.2)	16 (20.8)
> 1 Subspecialty	13 (9.0)	0
Highest level of education
MD/MBBS/gastroenterology fellowship	73 (50.7)	50 (64.9)
Master’s degree	34 (23.6)	10 (13.0)
PhD or equivalent	37 (25.7)	17 (22.1)
Primary workplace
Public hospital	85 (59.0)	56 (72.7)
Private hospital	23 (16.0)	20 (26.0)
University hospital	36 (25.0)	1 (1.3)
No. of IBD patients consulted weekly
< 5 Patients	76 (52.8)	35 (45.5)
≥ 5 Patients	68 (47.2)	42 (54.6)
Regular IBD MDT meeting with members	71 (49.3)	35 (45.5)
Registered nurse	29 (40.8)	27 (77.1)
Dietician	17 (23.9)	19 (54.3)
Pathologist	50 (70.4)	17 (48.6)
Surgeon	50 (70.4)	30 (85.7)
Pharmacist	7 (9.9)	0
Radiologist	43 (60.6)	29 (82.9)
Psychologist	3 (4.2)	4 (11.4)

Values are presented as number (%).

IBD, inflammatory bowel disease; MD, Doctor of Medicine; MBBS, Bachelor of Medicine, Bachelor of Surgery; PhD, Doctor of Philosophy; MDT, multidisciplinary team.

Table 2.

Predictive Factors for Histological Knowledge

Factor	Univariate analysis^a		Multivariable analysis^b
Factor	Crude OR	P-value	Adjusted OR	P-value
All respondents
IBD specialist	3.55 (1.86–6.75)	< 0.01	2.66 (1.30–5.45)	0.01
PhD degree	2.81 (1.40–5.68)	< 0.01	1.82 (0.84–3.93)	0.13
Work in public hospital or university	1.81 (0.79–4.16)	0.16
Graduate	1.48 (0.65–3.38)	0.35
MDT participation	2.14 (1.18–3.89)	0.01	1.32 (0.67–2.59)	0.42
Asian gastroenterologists
IBD specialist	3.00 (1.33–6.78)	0.01
PhD degree	1.96 (0.80–4.78)	0.14
Work in public hospital or university	0.57 (0.16–2.10)	0.40
Graduate	1.37 (0.47–3.98)	0.56
MDT participation	1.86 (0.87–3.94)	0.11
Australian gastroenterologists
IBD specialist	4.40 (1.45–13.40)	0.01	2.85 (0.70–11.57)	0.14
PhD degree	5.49 (1.68–17.99)	0.01	4.11 (1.18–14.40)	0.03
Work in public hospital or university	3.45 (0.85–13.93)	0.08
Graduate	1.45 (0.36–5.85)	0.60
MDT participation	2.92 (1.00–8.50)	0.05	1.34 (0.34–5.21)	0.68

^a Univariable analysis was conducted using a knowledge score cutoff threshold of greater than 10 out of 19.

^b Multivariate analysis was conducted using significant variables in the univariable analysis with a P-value of less than 0.05.

OR, odds ratio; IBD, inflammatory bowel disease; PhD, Doctor of Philosophy; MDT, multidisciplinary team.

REFERENCES

1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet 2017;389:1756–1770.Article PubMed
2. Ng SC, Kaplan GG, Tang W, et al. Population density and risk of inflammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific. Am J Gastroenterol 2019;114:107–115.Article PubMed PDF
3. Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021;18:56–66.Article PubMed PMC PDF
4. Gros B, Kaplan GG. Ulcerative colitis in adults: a review. JAMA 2023;330:951–965.Article PubMed
5. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021;160:1570–1583.Article PubMed
6. Gupta A, Yu A, Peyrin-Biroulet L, Ananthakrishnan AN. Treat to target: the role of histologic healing in inflammatory bowel diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2021;19:1800–1813.Article PubMed
7. Yoon H, Jangi S, Dulai PS, et al. Incremental benefit of achieving endoscopic and histologic remission in patients with ulcerative colitis: a systematic review and meta-analysis. Gastroenterology 2020;159:1262–1275.Article PubMed PMC
8. Christensen B, Erlich J, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic healing is more strongly associated with clinical outcomes in ileal Crohn’s disease than endoscopic healing. Clin Gastroenterol Hepatol 2020;18:2518–2525.Article PubMed PMC
9. Pudipeddi A, Fung C, Christensen B, et al. Knowledge and attitudes towards the use of histological assessments in ulcerative colitis by gastroenterologists vs pathologists. World J Gastroenterol 2023;29:378–389.Article PubMed PMC
10. Magro F, Doherty G, Peyrin-Biroulet L, et al. ECCO Position Paper: harmonization of the approach to ulcerative colitis histopathology. J Crohns Colitis 2020;14:1503–1511.Article PubMed PDF
11. Magro F, Sabino J, Rosini F, et al. ECCO position on harmonisation of Crohn’s disease mucosal histopathology. J Crohns Colitis 2022;16:876–883.Article PubMed PDF
12. Feakins RM, British Society of Gastroenterology. Inflammatory bowel disease biopsies: updated British Society of Gastroenterology reporting guidelines. J Clin Pathol 2013;66:1005–1026.Article PubMed
13. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. Br Med J 1956;1:1315–1318.Article PubMed PMC
14. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32:174–178.Article PubMed PMC
15. Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut 2000;47:404–409.Article PubMed PMC
16. Marchal-Bressenot A, Salleron J, Boulagnon-Rombi C, et al. Development and validation of the Nancy histological index for UC. Gut 2017;66:43–49.Article PubMed
17. Mosli MH, Feagan BG, Zou G, et al. Development and validation of a histological index for UC. Gut 2017;66:50–58.Article PubMed
18. Danese S, Roda G, Peyrin-Biroulet L. Evolving therapeutic goals in ulcerative colitis: towards disease clearance. Nat Rev Gastroenterol Hepatol 2020;17:1–2.Article PubMed PDF
19. D’Amico F, Guillo L, Baumann C, Danese S, Peyrin-Biroulet L. Histological disease activity measured by the Nancy index is associated with long-term outcomes in patients with ulcerative colitis. J Crohns Colitis 2021;15:1631–1640.Article PubMed PDF
20. Park S, Abdi T, Gentry M, Laine L. Histological disease activity as a predictor of clinical relapse among patients with ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2016;111:1692–1701.Article PubMed PDF
21. Ma C, Sedano R, Almradi A, et al. An international consensus to standardize integration of histopathology in ulcerative colitis clinical trials. Gastroenterology 2021;160:2291–2302.Article PubMed PMC
22. Nardone OM, Iacucci M, Villanacci V, et al. Real-world use of endoscopic and histological indices in ulcerative colitis: results of a global survey. United European Gastroenterol J 2023;11:514–519.Article PubMed PMC
23. Park J, Jeong GH, Song M, et al. The global, regional, and national burden of inflammatory bowel diseases, 1990-2019: a systematic analysis for the global burden of disease study 2019. Dig Liver Dis 2023;55:1352–1359.Article PubMed

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Comparison of the performance between an AI-based vision transformer and human endoscopists in predicting the endoscopic and histologic activities of ulcerative colitis
Yuan-Yen Chang, Han-Po Yang, Yang-Yuan Chen, Hsu-Heng Yen
DIGITAL HEALTH.2026;[Epub] CrossRef
Asia Pacific association of gastroenterology consensus statements on histopathological evaluation of inflammatory bowel diseases
Rupert W. Leong, Thanaboon Chaemsupaphan, Huiyu Lin, Wee Chian Lim, Choon Jin Ooi, John D. Chetwood, Ren Mao, Hsin Yun Wu, Shu Chen Wei, Govind Makharia, Vineet Ahuja, Rupa Banerjee, Raja Atreya, Julajak Limsrivilai, Satimai Aniwan, Pises Pisespongsa, Ida
Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Knowledge and perspectives towards the use of histology in inflammatory bowel disease by gastroenterologists across the Asia-Pacific region

Intest Res. 2025;23(3):338-346. Published online December 2, 2024

DOI: https://doi.org/10.5217/ir.2024.00086

XML Download

Figure

Related articles

The impact of sleep quality on the prognosis of inflammatory bowel disease commonly overlooked by gastroenterologists

Knowledge and perspectives towards the use of histology in inflammatory bowel disease by gastroenterologists across the Asia-Pacific region

Fig. 1. Mean inflammatory bowel disease (IBD) histological knowledge scores of overall respondents and the 4 most responsive countries. Values are shown in mean±standard deviation.

Fig. 2. Forest plot comparing inflammatory bowel disease (IBD) histological knowledge of all respondents according to IBD subspecialty, educational degree, primary workplace, level of training, and participation in multidisciplinary team meeting. Values are shown in mean±standard deviation and mean difference with 95% confidence interval. PhD, Doctor of Philosophy; MDT, multidisciplinary team.

Fig. 3. Comparison of knowledge of histological remission endpoint for each scoring system. (A-C) The remission endpoints of Geboes score, Nancy histological index, and Robart’s histological index are ≤2, 0, and ≤3, respectively.

Fig. 4. Attitudes of gastroenterologists in the Asia-Pacific region towards the role of histology in clinical practice (A) and the current preference of using histological index in routine practice (B).

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Knowledge and perspectives towards the use of histology in inflammatory bowel disease by gastroenterologists across the Asia-Pacific region

Variable	Asian (n = 144)	Australian (n = 77)
Age group
21–30 yr	3 (2.1)	4 (5.2)
31–40 yr	75 (52.1)	30 (39.0)
41–50 yr	37 (25.7)	15 (19.5)
51–60 yr	21 (14.6)	19 (24.7)
> 60 yr	8 (5.6)	9 (11.7)
Countries of participants
Australia		77 (34.8)
Brunei	4 (1.8)
China	2 (0.9)
Hong Kong	9 (4.1)
India	1 (0.5)
Japan	5 (2.3)
Malaysia	6 (2.7)
Mongolia	1 (0.5)
Singapore	32 (14.5)
Taiwan	41 (18.6)
Thailand	21 (9.5)
South Korea	22 (10.0)
Predominant subspecialty (self-reported)
General gastroenterologist	44 (30.6)	32 (41.6)
Intervention endoscopist	18 (12.5)	4 (5.2)
Hepatologist	9 (6.3)	4 (5.2)
IBD	54 (37.5)	21 (27.3)
Gastroenterology trainee/fellow	19 (13.2)	16 (20.8)
> 1 Subspecialty	13 (9.0)	0
Highest level of education
MD/MBBS/gastroenterology fellowship	73 (50.7)	50 (64.9)
Master’s degree	34 (23.6)	10 (13.0)
PhD or equivalent	37 (25.7)	17 (22.1)
Primary workplace
Public hospital	85 (59.0)	56 (72.7)
Private hospital	23 (16.0)	20 (26.0)
University hospital	36 (25.0)	1 (1.3)
No. of IBD patients consulted weekly
< 5 Patients	76 (52.8)	35 (45.5)
≥ 5 Patients	68 (47.2)	42 (54.6)
Regular IBD MDT meeting with members	71 (49.3)	35 (45.5)
Registered nurse	29 (40.8)	27 (77.1)
Dietician	17 (23.9)	19 (54.3)
Pathologist	50 (70.4)	17 (48.6)
Surgeon	50 (70.4)	30 (85.7)
Pharmacist	7 (9.9)	0
Radiologist	43 (60.6)	29 (82.9)
Psychologist	3 (4.2)	4 (11.4)

Factor	Univariate analysis^a		Multivariable analysis^b
Factor	Crude OR	P-value	Adjusted OR	P-value
All respondents
IBD specialist	3.55 (1.86–6.75)	< 0.01	2.66 (1.30–5.45)	0.01
PhD degree	2.81 (1.40–5.68)	< 0.01	1.82 (0.84–3.93)	0.13
Work in public hospital or university	1.81 (0.79–4.16)	0.16
Graduate	1.48 (0.65–3.38)	0.35
MDT participation	2.14 (1.18–3.89)	0.01	1.32 (0.67–2.59)	0.42
Asian gastroenterologists
IBD specialist	3.00 (1.33–6.78)	0.01
PhD degree	1.96 (0.80–4.78)	0.14
Work in public hospital or university	0.57 (0.16–2.10)	0.40
Graduate	1.37 (0.47–3.98)	0.56
MDT participation	1.86 (0.87–3.94)	0.11
Australian gastroenterologists
IBD specialist	4.40 (1.45–13.40)	0.01	2.85 (0.70–11.57)	0.14
PhD degree	5.49 (1.68–17.99)	0.01	4.11 (1.18–14.40)	0.03
Work in public hospital or university	3.45 (0.85–13.93)	0.08
Graduate	1.45 (0.36–5.85)	0.60
MDT participation	2.92 (1.00–8.50)	0.05	1.34 (0.34–5.21)	0.68

Table 1. Demographic Data

Values are presented as number (%).

IBD, inflammatory bowel disease; MD, Doctor of Medicine; MBBS, Bachelor of Medicine, Bachelor of Surgery; PhD, Doctor of Philosophy; MDT, multidisciplinary team.

Table 2. Predictive Factors for Histological Knowledge

Univariable analysis was conducted using a knowledge score cutoff threshold of greater than 10 out of 19.

Multivariate analysis was conducted using significant variables in the univariable analysis with a P-value of less than 0.05.

OR, odds ratio; IBD, inflammatory bowel disease; PhD, Doctor of Philosophy; MDT, multidisciplinary team.